In translational studies, residual tumor specimens collected from women with operable ER+ breast cancer following neoadjuvant letrozole contain a significantly enriched CD44+/CD24low/− subpopulation and upregulation of mesenchymal genes as compared to their pre-treatment tumor [20]. The gene discussed is CD44; the disease is breast cancer.